Switching to Biosimilars: what do patients think?

  • Research type

    Research Study

  • Full title

    Switching to Biosimilars: What do patients think?

  • IRAS ID

    254016

  • Contact name

    David Coady

  • Contact email

    d.coady@nhs.net

  • Sponsor organisation

    South Tyneside and Sunderland NHS FT

  • Duration of Study in the UK

    0 years, 8 months, 31 days

  • Research summary

    Biologic drugs have been routinely used in Rheumatology for over 15 years. The most common of these are the anti-TNF drugs (as they inhibit tumour necrosis factor). They effectively treat inflammation in conditions such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, but they are expensive.

    Biosimilar drugs are now being produced. These are copies of the originator biologic but may not be exactly identical (hence "biosimilar"). Biosimilars have been licensed for use in rheumatological conditions in recent years, and have the advantage of a 25-30% cost saving. Guidance from the National Institute for Clinical Excellence (NICE) suggests using the lowest cost anti TNF inhibitor where possible, however there are currently no data on patients' experiences of switching between the two types of drug.

    We are interested in patients' views on switching to biosimilars, what concerns they may have and what we as Health Care providers can do to support them and make the transition easier.

    We propose to hold face to face in depth interviews (approximately 45 minutes) with up to 15 adult patients who are being treated for the above conditions. They will have either switched to biosimilars already or be about to do so. We will explore their experiences and concerns using open ended questions.
    This study will run only at City Hospitals Sunderland where eligible patients will be approached at routine Rheumatology clinics. Participation in the study will last from when consent is signed to when the interview has been completed so can all be done in a single visit. The patients will receive a small gift voucher as a token of appreciation for participating.

    We hope that the results of this pilot study will enable us to create a questionnaire for wider use in the next phase of our research.

  • REC name

    East of Scotland Research Ethics Service REC 2

  • REC reference

    19/ES/0114

  • Date of REC Opinion

    1 Oct 2019

  • REC opinion

    Further Information Favourable Opinion